Aditxt Inc.

News & Events

Press Releases

In The Media

1. Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

   GlobeNewswire MAY 19, 2025 8:00 AM EDT
   NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...
   READ ARTICLE

2. Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

   Business Wire MAY 19, 2025 8:00 AM EDT
   Will eliminate approximately $16M in closing obligations Aditxt, Inc. (NASDAQ: ADTX) ...
   READ ARTICLE

3. Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt(TM), and Dr. Friedrich Kapp, Co-CEO of Adimune(TM), to Discuss Progress of Lead Therapeutic Candidate ADI-100(TM)

   Business Wire MAY 2, 2025 9:00 AM EDT
   Event Begins Today at 11:30 a.m. ET Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "C...
   READ ARTICLE

4. KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

   Business Wire APR 17, 2025 9:08 PM EDT
   Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 &...
   READ ARTICLE

5. KILL Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune(TM)

   Business Wire APR 17, 2025 9:03 PM EDT
   Aditxt, Inc. requests that their press release NewsItemId: 20250417385764 “Dr. Charles How...
   READ ARTICLE

6. Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune(TM)

   Business Wire APR 17, 2025 8:15 AM EDT
   Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerat...
   READ ARTICLE

7. Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

   Business Wire APR 16, 2025 8:15 AM EDT
   Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic...
   READ ARTICLE

8. Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

   Business Wire APR 14, 2025 8:15 AM EDT
   Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune ...
   READ ARTICLE

9. Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

   Business Wire APR 11, 2025 8:15 AM EDT
   The event will begin today at 11:30 a.m. ET Aditxt, Inc. (NASDAQ: ADTX) (“Ad...
   READ ARTICLE

10. Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

    Business Wire APR 9, 2025 8:15 AM EDT
    Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social inn...
    READ ARTICLE